Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Bupivacaine is an amide local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. Epinephrine is a vasoconstrictor that prolongs bupivacaine's effect by reducing vascular absorption.
Bupivacaine is an amide local anesthetic that blocks sodium channels on neuronal membranes, inhibiting the initiation and propagation of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the duration of action and reduces systemic absorption.
Local or regional anesthesia for surgical procedures,Dental anesthesia,Obstetric anesthesia (e.g., epidural for labor)
Local and regional anesthesia for surgical procedures,Epidural anesthesia for labor and delivery,Peripheral nerve blocks,Dental procedures (off-label),Spinal anesthesia (off-label)
Maximum dose of bupivacaine: 2 mg/kg (not to exceed 175 mg); with epinephrine: 3 mg/kg (not to exceed 225 mg). Administer via local infiltration, peripheral nerve block, epidural, or caudal block. Dose depends on the anesthetic procedure. Repeated doses may be given at intervals of 3-6 hours. Maximum single dose for epidural: 50 mg initially, then 10-25 mg per segment as needed.
For local infiltration: 0.25-0.5% solution, up to 30 m L (75-175 mg bupivacaine) with epinephrine 1:200,000, not to exceed 3 mg/kg bupivacaine. For peripheral nerve block: 0.25-0.5% solution, up to 40 m L (100-200 mg). For epidural: 0.5% solution, 10-20 m L (50-100 mg). Maximum single dose: 225 mg with epinephrine.
Terminal elimination half-life of bupivacaine is approximately 2.7 hours (range 1.5–5.5 hours) in adults. In neonates, half-life is prolonged (8–12 hours) due to immature hepatic function. The half-life of epinephrine is very short (~1–2 minutes) due to rapid metabolism.
Terminal elimination half-life in adults is 2.7–3.4 hours (mean ~3.0 h). In neonates, it is prolonged (8–12 hours) due to immature hepatic function. Clinically, this supports continuous infusion intervals of 6–12 hours for epidural analgesia.
Bupivacaine is metabolized primarily in the liver via CYP1A2 and CYP3A4 to pipecoloxylidine. Epinephrine is metabolized by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO).
Bupivacaine is metabolized primarily in the liver via conjugation with glucuronic acid and via CYP3A4-mediated N-dealkylation to pipecolylxylidine. Epinephrine is metabolized by monoamine oxidase and catechol-O-methyltransferase.
Bupivacaine is primarily metabolized in the liver via CYP3A4 and is excreted renally as metabolites (approximately 95% in urine) and less than 5% unchanged. Epinephrine is rapidly metabolized by COMT and MAO and excreted renally as metabolites.
Bupivacaine is metabolized in the liver primarily via CYP3A4 and CYP1A2. Approximately 6% is excreted unchanged in urine. The major metabolite, pipecolylxylidine (PPX), is excreted renally (80–90% of dose) with 2–5% as desbutylbupivacaine. Fecal elimination accounts for <5%. Biliary excretion of metabolites occurs but is minimal.
Bupivacaine is highly protein-bound (approximately 95%) primarily to alpha-1-acid glycoprotein (AAG) and albumin. Epinephrine is bound to AAG (30–40%) and albumin (10–20%).
~95% bound to alpha-1-acid glycoprotein (AAG) and, to a lesser extent, albumin. Binding is saturable; increased free fraction in acidosis or low AAG (e.g., neonates, pregnancy).
Bupivacaine Vd is 0.5–1.0 L/kg. Higher Vd in neonates (1.5–2.0 L/kg) due to increased body fat and decreased protein binding. Epinephrine Vd is 0.2–0.4 L/kg.
Vd: 0.8–1.3 L/kg (mean ~0.9 L/kg). This indicates extensive tissue distribution, including highly perfused organs (brain, heart, liver). Higher Vd in neonates (~2.0 L/kg).
Bupivacaine: Epidural: 100% (bypasses first-pass). Peripheral nerve block: 100%. Intrathecal: 100%. Oral: <10% due to extensive first-pass metabolism. Epinephrine: Bioavailability is 100% for parenteral routes; oral is negligible due to gastrointestinal and hepatic metabolism.
Bioavailability via epidural administration: ~100% (systemic absorption from the epidural space). Intrathecal: ~100% (but small dose, usually 2–3 mg). Subcutaneous: ~100% (absorption delayed by vasoconstriction). Oral: not available; high first-pass metabolism.
No specific dose adjustment for bupivacaine is recommended for renal impairment. Use with caution in severe renal failure (GFR <15 m L/min) due to potential accumulation of metabolites.
No dose adjustment required for mild to moderate renal impairment (GFR >= 30 m L/min). For severe renal impairment (GFR < 30 m L/min): use with caution, reduce dose by 25-50% and monitor for systemic toxicity due to potential accumulation of metabolites.
For Child-Pugh A: no adjustment. Child-Pugh B: reduce total dose by 25-50%. Child-Pugh C: contraindicated or use with extreme caution with significant dose reduction (e.g., 50-75% reduction) and close monitoring.
Child-Pugh Class A: no dose adjustment needed. Child-Pugh Class B: reduce dose by 25-50%. Child-Pugh Class C: avoid use or use with extreme caution, consider alternative local anesthetic.
For children >12 years, same as adult. For children ≤12 years, weight-based dosing: bupivacaine without epinephrine: 0.5-1 mg/kg; with epinephrine: 1-2 mg/kg. Maximum single dose: without epinephrine: 2 mg/kg; with epinephrine: 3 mg/kg. Administer by infiltration or regional block. Not recommended in infants <12 months.
For infiltration: 0.25-0.5% solution, 0.5-2 mg/kg bupivacaine with epinephrine, maximum single dose 2 mg/kg. For caudal epidural: 0.25-0.5% solution, 1-2 mg/kg. For peripheral nerve block: 0.25-0.5% solution, up to 2 mg/kg. Maximum total dose: 2 mg/kg for children <12 years.
Reduce dose by 25-50% in elderly patients due to increased sensitivity and reduced clearance. Lower concentrations (e.g., 0.25%) may be used. Monitor for cardiotoxic effects. Use minimal effective dose.
Reduce dose by 20-30% due to decreased clearance and increased sensitivity. Use lower concentrations (0.25-0.375%) and titrate slowly. Maximum dose: 2 mg/kg bupivacaine with epinephrine, not to exceed 150 mg.
Risk of cardiac arrest and severe hypotension when used for epidural anesthesia in obstetrics; risk of severe neurologic injury (e.g., cauda equina syndrome) with continuous spinal anesthesia.
There have been reports of cardiac arrest and death during use of bupivacaine for epidural anesthesia in obstetrical patients. Resuscitation has been difficult or impossible despite adequate preparation and proper management. Bupivacaine with epinephrine is not recommended for obstetrical paracervical block anesthesia for the same reason.
Risk of systemic toxicity (CNS and cardiovascular) with accidental intravascular injection; use with caution in patients with hepatic disease, severe hypertension, or cardiovascular disease; avoid in patients with arrhythmias or hypotension.
Risk of cardiac toxicity, especially with inadvertent intravascular injection,Neurologic damage following spinal or epidural administration,Methemoglobinemia in susceptible patients,Avoid use in patients with severe hypotension or hypovolemia,Use caution in patients with hepatic impairment, as metabolism may be reduced,Increased risk of cardiotoxicity in elderly or debilitated patients,Avoid concurrent use with other local anesthetics or class I antiarrhythmics
Hypersensitivity to bupivacaine or epinephrine; severe hypotension; cardiogenic shock; use in intravenous regional anesthesia (Bier block) due to risk of toxicity; concomitant use with MAOIs or tricyclic antidepressants due to hypertensive crisis.
Hypersensitivity to bupivacaine, epinephrine, or any component of the formulation,Severe hypertension or untreated thyrotoxicosis (due to epinephrine component),Concurrent use with MAO inhibitors or tricyclic antidepressants (due to epinephrine component),Use for paracervical block in obstetrics (black box warning),Severe hypotension or cardiogenic shock,Complete heart block or severe conduction disturbances
No significant food interactions. Avoid alcohol consumption until effects of anesthesia have worn off to prevent dizziness or syncope.
No specific food interactions. Caffeine-containing beverages may be consumed as usual. No dietary restrictions.
Bupivacaine with epinephrine is classified as FDA Pregnancy Category C. Animal studies have shown adverse fetal effects at high doses, but no adequate human studies exist. First trimester: Risk cannot be ruled out; use only if clearly needed. Second/third trimester: May cause fetal bradycardia and acidosis if absorbed systemically, especially with paracervical block. Avoid use during delivery due to potential for neonatal depression and reduced uterine blood flow from epinephrine.
FDA Pregnancy Category C. First trimester: No adequate studies; animal studies show no teratogenicity at clinically relevant doses. Second trimester: No known teratogenic risk from bupivacaine; epinephrine may reduce uterine blood flow. Third trimester: Risk of fetal bradycardia, hypoxia, and acidosis with paracervical block; avoid in obstetric anesthesia due to potential for fetal acidosis and maternal seizures.
Bupivacaine is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 0.3-0.5. Epinephrine is poorly excreted and rapidly metabolized. The American Academy of Pediatrics considers bupivacaine compatible with breastfeeding. However, observe infant for signs of local anesthetic toxicity (e.g., irritability, apnea) if used repeatedly.
Bupivacaine is excreted into breast milk in small amounts (M/P ratio approximately 0.3). No adverse effects reported in nursing infants. Epinephrine is not orally bioavailable. Use with caution; infant exposure is minimal.
Pregnancy may reduce the required dose of bupivacaine due to increased cardiac output and altered protein binding. Standard dosing adjustments are not defined, but cautious dose reduction (e.g., 20-30%) is recommended for epidural or spinal anesthesia to avoid high plasma levels. Epinephrine concentrations should be kept low to minimize uterine vasoconstriction.
No routine dose adjustment required; however, pregnancy may increase sensitivity to local anesthetics due to hormonal changes. Use lowest effective dose. Increased vascularity may require higher doses for epidural anesthesia; reduce dose for paracervical blocks to avoid fetal exposure.
Bupivacaine-epinephrine combination provides prolonged local anesthesia with vasoconstriction. Maximum dose: bupivacaine 2 mg/kg (3 mg/kg with epinephrine). Avoid in paracervical block (0.25% bupivacaine with epinephrine) due to risk of fetal bradycardia. Contraindicated in severe hypotension, hypovolemia, or concurrent MAOI use. Do not use in patients with sulfite allergy (bisulfite preservative). Epinephrine concentration is 1:200,000 (5 mcg/m L).
Limit total bupivacaine dose to 2 mg/kg with epinephrine; avoid in paracervical block (obstetric) due to fetal toxicity. Do not use for IV regional anesthesia (Bier block) as cardiac toxicity risk is high. Epinephrine-containing formulation prolongs block duration and reduces systemic absorption but vasoconstriction may delay wound healing in certain tissues.
Report any signs of allergic reaction: hives, difficulty breathing, swelling of face/lips/tongue.,Numbness may last several hours; avoid chewing or testing the anesthetized area with hot objects.,If you experience chest pain, palpitations, severe headache, or shortness of breath after injection, seek immediate medical attention.,Do not drive or operate machinery until sensation fully returns.,Tell your doctor if you have high blood pressure, heart disease, thyroid problems, or are taking MAO inhibitors or tricyclic antidepressants.
This medicine is a local anesthetic used to numb a specific area of your body, often to prevent pain during surgery or dental procedures.,You may feel a burning sensation when the injection is first given, but numbness should occur quickly.,Avoid touching or scratching the numb area until sensation returns to prevent injury.,Report any signs of allergic reaction (rash, itching, swelling) or severe headache, stiff neck, or mental status changes after injection.,Do not drive or operate machinery until numbness wears off, as your coordination or reflexes may be impaired.
"The concurrent administration of nitrous oxide and bupivacaine may increase the risk of cardiovascular depression and arrhythmias due to synergistic cardiovascular depressant effects. Nitrous oxide can cause sympathetic nervous system activation and myocardial depression, while bupivacaine prolongs ventricular depolarization and increases the risk of reentrant arrhythmias, particularly at high doses. This combination may lead to hypotension, bradycardia, or more severe cardiac conduction abnormalities, especially in patients with preexisting cardiac disease."
"The coadministration of bupivacaine, a sodium channel blocker used for local anesthesia, with diclofenamide, a carbonic anhydrase inhibitor and diuretic, may lead to metabolic acidosis and altered electrolyte balance, thereby increasing the risk of bupivacaine-induced cardiotoxicity and central nervous system (CNS) toxicity. Diclofenamide can cause hypokalemia and hypocalcemia, which potentiate the sodium channel blocking effects of bupivacaine, resulting in arrhythmias, seizures, or other adverse effects. This interaction is clinically significant especially in patients with renal impairment or those on multiple electrolyte-altering medications."
"Oxymorphone, a potent mu-opioid receptor agonist, and bupivacaine, a local anesthetic that blocks sodium channels, both depress the central nervous system (CNS) and respiratory drive. Coadministration may lead to additive CNS and respiratory depression, increasing the risk of severe adverse effects such as hypotension, bradycardia, and respiratory arrest. Clinical outcomes include enhanced sedation, confusion, and possibly fatal respiratory compromise, especially in patients with compromised cardiovascular function or those receiving high doses of either agent."
"Epinephrine, a catecholamine with potent beta-2 adrenergic agonist activity, can antagonize the hypoglycemic effect of tolbutamide, a sulfonylurea insulin secretagogue. By stimulating hepatic gluconeogenesis and glycogenolysis, epinephrine increases blood glucose levels, potentially reducing tolbutamide's efficacy in lowering glucose. This interaction may lead to diminished glycemic control, particularly in diabetic patients under stress or during epinephrine administration for anaphylaxis or hypotension."
"Epinephrine, a non-selective alpha and beta adrenergic agonist, can antagonize the antihypertensive effects of clomipramine, a tricyclic antidepressant (TCA) that inhibits norepinephrine reuptake. Concomitant use may lead to enhanced sympathetic activity, potentially causing severe hypertension, tachycardia, and increased risk of arrhythmias. This interaction is particularly concerning during local anesthetic procedures involving epinephrine or systemic administration in patients on clomipramine."
"Epinephrine, a sympathomimetic amine with potent beta-2 adrenergic agonist activity, can directly antagonize the insulin-sensitizing effects of pioglitazone by stimulating glycogenolysis and gluconeogenesis, leading to increased hepatic glucose output and reduced peripheral glucose uptake. This functional antagonism may result in a significant elevation of blood glucose levels, thereby diminishing the therapeutic efficacy of pioglitazone in managing type 2 diabetes. In diabetic patients, the interaction may precipitate acute hyperglycemia, requiring dosage adjustments or alternative therapeutic strategies."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE vs MARCAINE HYDROCHLORIDE W/ EPINEPHRINE, answered by our medical review team.
BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE is a Alpha/Beta Agonist that works by Bupivacaine is an amide local anesthetic that blocks sodium channels, inhibiting nerve impulse conduction. Epinephrine is a vasoconstrictor that prolongs bupivacaine's effect by reducing vascular absorption.. MARCAINE HYDROCHLORIDE W/ EPINEPHRINE is a Alpha/Beta Agonist that works by Bupivacaine is an amide local anesthetic that blocks sodium channels on neuronal membranes, inhibiting the initiation and propagation of nerve impulses. Epinephrine is a vasoconstrictor that prolongs the duration of action and reduces systemic absorption.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE and MARCAINE HYDROCHLORIDE W/ EPINEPHRINE depend on the specific clinical indication. These are both Alpha/Beta Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE is: Maximum dose of bupivacaine: 2 mg/kg (not to exceed 175 mg); with epinephrine: 3 mg/kg (not to exceed 225 mg). Administer via local infiltration, peripheral nerve block, epidural, or caudal block. Dose depends on the anesthetic procedure. Repeated doses may be given at intervals of 3-6 hours. Maximum single dose for epidural: 50 mg initially, then 10-25 mg per segment as needed.. The standard adult dose of MARCAINE HYDROCHLORIDE W/ EPINEPHRINE is: For local infiltration: 0.25-0.5% solution, up to 30 m L (75-175 mg bupivacaine) with epinephrine 1:200,000, not to exceed 3 mg/kg bupivacaine. For peripheral nerve block: 0.25-0.5% solution, up to 40 m L (100-200 mg). For epidural: 0.5% solution, 10-20 m L (50-100 mg). Maximum single dose: 225 mg with epinephrine.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE and MARCAINE HYDROCHLORIDE W/ EPINEPHRINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BUPIVACAINE HYDROCHLORIDE AND EPINEPHRINE is classified as Category A/B. Bupivacaine with epinephrine is classified as FDA Pregnancy Category C. Animal studies have shown adverse fetal effects at high doses, but no adequate human studies exist. First tr. MARCAINE HYDROCHLORIDE W/ EPINEPHRINE is classified as Category A/B. FDA Pregnancy Category C. First trimester: No adequate studies; animal studies show no teratogenicity at clinically relevant doses. Second trimester: No known teratogenic risk from. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.